Citadel Advisors
DRMA icon

Citadel Advisors’s Dermata Therapeutics DRMA Stock Holding History

Citadel Advisors’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-117
Closed -$7.03K – 14469
2024
Q1 		$7.03K Buy
+117
New +$8.05K ﹤0.01% 13637
2023
Q3 		– Sell
-115
Closed -$28.5K – 14454
2023
Q2 		$28.5K Buy
+115
New +$31.4K ﹤0.01% 12408
2022
Q3 		– Sell
-33
Closed -$52K – 12823
2022
Q2 		$52K Buy
+33
New +$68K ﹤0.01% 11910

Other funds holding DRMA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's DRMA Position: Q2 2024 in Review

Citadel Advisors sold out of Dermata Therapeutics (DRMA) in Q2 2024, closing a stake of 117 shares — an estimated $7.03K sold.

Citadel Advisors first reported a position in DRMA in Q2 2022 and held it in 3 quarters. The position peaked at $52K in Q2 2022. 5 funds tracked by Wall St. Rank hold DRMA as of Q2 2024.

  • Citadel Advisors reported no remaining Dermata Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 117 Dermata Therapeutics shares in Q2 2024, an estimated $7.03K.
  • Citadel Advisors first reported a position in Dermata Therapeutics in Q2 2022 and held it in 3 quarters.
  • Citadel Advisors's Dermata Therapeutics position peaked at $52K in Q2 2022.
  • 5 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.